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Abstract Thyroid cancer (TC) is the most common type
of endocrine malignancy and accounts for nearly 3 % of all
malignancies. The incidence of TC in Spain was 5/100,000
in women and 1.9/100,000 in men in 2013. The diagnosis
of TC usually follows the identification of a thyroid nodule
on physical examination or as an incidental finding on
diagnostic imaging performed for other reasons. In most of
the cases, the prognosis is excellent but despite low
mortality rates, local recurrence occurs in up to 20 %, and
distant metastases can occur in approximately 10 % at
10 years. The better knowledge of molecular biology of TC
has allowed to the development of new targeted agents
directed to the main pathways involved in TC pathogene-
sis. Knowing all these new strategies will help us face the
therapeutic management of TC more effectively.
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Method–methodology
To identify the main topics published in medical literature,
a search in ‘‘PubMed’’ and ‘‘isiknowledge’’ (that includes
both full papers and abstracts) has been performed. Sen-
tences used were ‘‘thyroid carcinoma’’, ‘‘thyroid carcinoma
treatment’’, and ‘‘thyroid carcinoma antitarget therapies’’.
Main reviews on the topics: Clinical Guidelines of the
European Society of Endocrinology, ESMO clinical
guides, NCCN guides and American Thyroid Association
guidelines for TC, have been consulted.
Introduction
Thyroid cancer is the most common type of endocrine
malignancy and accounts for nearly 3 % of all malignancies
[1]. The incidence of thyroid cancer has increased nearly
threefold from 1975 to 2009. The age-adjusted incidence rate
of thyroid cancer in women is nearly three times that of men
(17.3/100,000 for women, 5.9/100,000 for men) [2]. The
cause of this disparity is unknown, but generally the less
aggressive types of thyroid cancer are more common in
women, whereas the more aggressive types have similar sex
distributions [3]. The incidence of thyroid cancer in Spain
was 5/100,000 in women and 1.9/100,000 in men in 2013.
Thyroid cancer is diagnosed at a higher rate among Cauca-
sians than other ethnic groups. The age-adjusted mortality
rate from thyroid cancer is the same in men and women, and
is roughly the same across ethnic groups [2].
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The only established environmental risk factor for thy-
roid carcinoma is exposure to ionizing radiation, and the
risk, particularly of papillary carcinoma, is greater in sub-
jects of younger age at exposure [4].
Thyroid cancer can be divided into three general sub-
types based on pathology: differentiated (papillary, follic-
ular, and Hu¨rthle cell), medullary, and anaplastic thyroid
cancers. Differentiated thyroid cancer, arising from thyroid
follicular epithelial cells, accounts for the vast majority
(90 %) of thyroid cancers. Of the differentiated cancers,
papillary cancer comprises about 85 % of cases compared
to about 10 % that have follicular histology, and 3 % that
are Hu¨rthle cell or oxyphil tumors. In general, stage for
stage, the prognosis of papillary and follicular cancer is
similar. Certain histologic subtypes of papillary cancer
have a worse prognosis (tall cell variant, columnar cell
variant, and diffuse sclerosing variant), as do more highly
invasive variants of follicular cancer.
The prognosis is excellent for most patients with thyroid
cancer; the overall 5-year relative survival for 2002–2008
from Surveillance, Epidemiology, and End Results pro-
gram geographic areas was 97.5 % [2]. Despite low mor-
tality rates, local recurrence occurs in up to 20 % of
patients, and distant metastases occur in approximately
10 % at 10 years [5].
Diagnosis
As in all thyroid cancers, the diagnosis of TC usually fol-
lows the identification of a thyroid nodule on physical
examination or as an incidental finding on diagnostic
imaging performed for other reasons. Occasionally, dis-
comfort in the neck or a hoarse voice or a change in collar
size can be presenting complaints.
The standard of care for the workup of a thyroid nodule
includes identification and characterization with ultraso-
nography. Using this modality, nodules and lymph nodes
can be identified as potentially malignant based on their
size and vascular properties. Nodules that are worrisome
due to recent growth or sonographic characteristics are
biopsied with fine-needle aspiration (FNA).
Patients with carcinoma for whom curative treatment with
surgery is planned should undergo neck ultrasonography to
identify lymph nodes that are likely to be involved, so that a
neck dissection can be performed to remove these nodes
where indicated. Routine preoperative measurement of
serum thyroglobulin (Tg) is not recommended.
Recommendation: Patients with carcinoma for whom
curative treatment with surgery is planned should undergo
neck ultrasonography.
Surgical treatment
For patients with thyroid cancer[1 cm, the initial surgical
procedure should be a near-total or total thyroidectomy
unless there are contraindications to this surgery. Thyroid
lobectomy alone may be sufficient treatment for small
(\1 cm), low-risk, unifocal, intrathyroidal papillary carci-
nomas in the absence of prior head and neck irradiation or
radiologically or clinically involved cervical nodal
metastases.
The benefit of prophylactic central node dissection in the
absence of evidence of nodal disease is controversial.
There is no evidence that it improves recurrence or mor-
tality rate, but it permits an accurate staging of the disease
that may guide subsequent treatment and follow-up [6].
Compartment-oriented microdissection of lymph nodes
should be performed in cases of preoperatively suspected
and/or intraoperatively proven lymph node metastases in
follicular thyroid cancer.
Following thyroidectomy, neck ultrasound, and high-
dose radioactive iodine (RAI) can help identify and treat
any residual disease, respectively. MRI, non-enhanced CT,
and serum Tg levels are used to identify extrathyroidal
disease. Common sites of metastatic spread include neck,
chest, bone, and brain.
Recommendation: following thyroidectomy, neck
ultrasound, and high-dose radioactive iodine (RAI) can
help identify and treat any residual disease, respectively.
Staging
Staging takes into consideration tumor characteristics,
metastasis, and patient age (Table 1). Although all staging
systems are able to predict high or low risk of cancer
mortality, they fail to predict the risk of recurrence. To
overcome this limitation, both the American Thyroid
Association (ATA) and the European Thyroid Association
(ETA) have recently published practical guidelines [6] in
which they graded the risk of recurrence in three categories
of increasing risk on the basis of tumor-related parameters
(pTNM and histological variant) integrated with other
clinical features, including the result of the post-ablative
whole-body scan (WBS) and serum Tg measurement
(Table 2).
Postoperative adjuvant therapy in differentiated thyroid
cancer (DTC)
Two main strategies are recommended after radical surgery
of primary DTC: postoperative radioactive iodine (RAI)
therapy to eliminate the postsurgical thyroid remnant and
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TSH suppression therapy using high doses of levothyroxine
(LT4) to reduce the risk of recurrence.
RAI ablation is recommended in all patients with high-
risk DTC defined as tumor size [4 cm and extrathyroidal
invasion. RAI ablation is also recommended in selected
patients with intermediate risk, with 1–4 cm tumors limited
to the thyroid and additional poor prognostic factors, such
as lymph node metastases, age [45 years old, aggressive
histological features or multifocal disease. To increase the
efficacy of RAI, treatment with RAI should be applied with
high levels of TSH that could be achieved by elevation of
endogenous TSH removing intake of LT4 or with recom-
binant TSH (rhTHS) previous RAI administration [7].
Doses of RAI between 30 and 100 mCi are usually enough
in adjuvant setting to remove uptake in iodine scan and to
obtain undetectable stimulated thyroglobulin levels after
treatment. The current trend is to use lower doses, mainly
in low-risk patients, showing in randomized clinical trials
equivalence between high and low doses [8].
Accurate follow-up during the first year after RAI
adjuvant therapy with stimulated thyroglobulin levels,
thyroglobulin antibodies, neck ultrasound, and RAI whole-
body scans will classify patients unlikely to experience
tumor relapse or higher risk patients, and proceed with
long-term or closer follow-up strategies [9].
Recommendations: to increase the efficacy of RAI,
treatment with RAI should be applied with high levels of
TSH that could be achieved by elevation of endogenous
TSH removing intake of LT4 or with recombinant TSH
(rhTHS) previous RAI administration (category 1). The
current trend is to use lower doses, mainly in low-risk
patients, showing in randomized clinical trials equivalence
between high and low doses. Accurate follow-up during
the first year after RAI adjuvant therapy with stimulated
thyroglobulin levels, thyroglobulin antibodies, neck
ultrasound, and RAI whole-body scans will classify
patients unlikely to experience tumor relapse or higher
risk patients, and proceed with long-term or closer follow-
up strategies.
Treatment of tumor relapse/metastatic DTC
Tumor relapse in patients with DTC is not infrequent
(5–20 % of locoregional relapse and 10–15 % of distant
metastases). Treatment algorithm should be guided by the
following criteria, in order of preference: surgical excision
of locoregional or isolated distant metastasis in potentially
curable patients; RAI therapy for patients with uptake in
iodine scans; wait-and-see policy in patients with low
tumor burden, asymptomatic and with no evidence of
disease progression; new targeted agents for RAI-refrac-
tory DTC; and external beam radiotherapy for unresectable
locoregional disease, symptomatic bone metastases, and
central nervous system spread (Fig. 1).
Treatment of lung micrometastases with RAI therapy is
highly effective and potentially curative, sessions should be
repeated every 6–12 months as long as there is uptake of
iodine, and complete remission is achieved or disease
progression is documented, with reduction in iodine con-
centration or on reaching high cumulative doses of RAI
[10]. RAI therapy is also effective for macrometastases in
the lung and other sites, but complete responses are unusual
and prognosis remains poor. Treatment cycles should be
repeated while clinical benefit is observed (reduction in
tumor burden, decrease in thyroglobulin levels, and
symptomatic improvement) and until metastatic disease
loses the iodine uptake capability or on reaching high
Table 1 TNM classification system for differentiated thyroid
carcinoma
T1 Tumor diameter 2 cm or smaller
T2 Primary tumor diameter [2–4 cm
T3 Primary tumor diameter [4 cm limited to the thyroid
or with minimal extrathyroidal extension
T4a Tumor of any size extending beyond the thyroid
capsule to invade subcutaneous soft tissues, larynx,
trachea, esophagus, or recurrent laryngeal nerve
T4b Tumor invades prevertebral fascia or encases carotid
artery or mediastinal vessels
TX Primary tumor size unknown, but without
extrathyroidal invasion
N0 No metastatic nodes
N1a Metastases to level VI (pretracheal, paratracheal, and
prelaryngeal/Delphian lymph nodes)
N1b Metastasis to unilateral, bilateral, contralateral cervical
or superior mediastinal nodes
NX Nodes not assessed at surgery
M0 No distant metastases
M1 Distant metastases
MX Distant metastases not assessed
Stages
Patient age \45 years Patient age 45 years or older
Stage I Any T, any N, M0 T1, N0, M0
Stage II Any T, any N, M1 T2, N0, M0










Stage IVB T4b, Any N, M0
Stage IVC Any T, Any N, M1
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cumulative doses. Doses of RAI therapy for metastatic
disease are empiric, from 100 to 200 mCi.
Up to two-thirds of patients with distant metastases or
unresectable locoregional disease will become RAI-
refractory. The main criteria to define RAI-refractoriness
include: RAI non-avid tumor lesions, loss of uptake of
previous RAI-avid lesions, evidence of tumor progression
after 12–16 months of RAI therapy, and FDG-PET scan
Table 2 Risk stratification according to the ATA and ETA guidelines
ATA risk stratification low risk Intermediate risk High risk
No local or distant metastases
All macroscopic tumor has been resected
No tumor invasion of locoregional tissues or
structures
No aggressive histology or vascular invasion
If 131I was given, no 131I uptake outside the
thyroid bed on the post-therapeutic WBS
Microscopic invasion of tumor into the perithyroidal
soft tissues at initial surgery
Cervical lymph node metastases or 131I uptake
outside the thyroid bed on the post-therapeutic
WBS





Thyroglobulinemia out of proportion to
what is seen on the post-ablative scan
ETA risk stratification very low risk Low risk High risk
Complete surgery
Patients with unifocal microcarcinoma (\1 cm)
with no extension beyond the thyroid capsule and
without lymph node metastases
No local or distant metastases




Less than total thyroidectomy
Tumor invasion of locoregional
tissues or structures




Fig. 1 Treatment algorithm for locally relapsed or metastatic DTC
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uptake. Until recently, no effective therapy was available in
RAI-refractory setting, and classical chemotherapy com-
binations did not show significant activity in many clinical
trials. The better knowledge of molecular biology of thy-
roid cancer has allowed to the development of new targeted
agents directed to the angiogenesis process and the main
pathways involved in thyroid cancer pathogenesis [11].
Two randomized, placebo-controlled phase III studies have
demonstrated the efficacy of multikinase inhibitors, so-
rafenib [12] and lenvatinib [13], in RAI-refractory DTC
patients. Sorafenib and lenvatinib demonstrated a statisti-
cally significant improvement in progression-free survival,
with significant increase in response rates in all subgroups
of patients with RAI-refractory DTC. Sorafenib has been
the first effective drug in this setting approved by regula-
tory authorities worldwide (category 1), and lenvatinib is
expected to be approved in the near future. Many other
targeted therapies are in clinical development in RAI-
refractory DTC, including multikinase inhibitors with a
different spectrum of kinase activity to avoid resistance to
previous tyrosine kinase inhibitors and inhibitors of spe-
cific alterations of DTC patients, such as BRAF or MEK
inhibitors for BRAF mutant population.
Recommendations: Treatment of lung micrometastases
with RAI therapy is highly effective and potentially cura-
tive, and sessions should be repeated every 6–12 months as
long as uptake of iodine is present, complete remission is
achieved or disease progression is documented, with
reduction in iodine concentration or on reaching high
cumulative doses of RAI. Sorafenib has been the first
effective drug in this setting approved by regulatory
authorities worldwide in RAI-refractory DTC patients.
Medullary thyroid carcinoma (MTC)
MTC is a neuroendocrine-derived malignancy that
accounts for 2–8 % of primary thyroid tumors depending
on the series. It is estimated that around 50 patients are
diagnosed with advanced MTC patients every year in Spain
[11]. With regard to the activity of systemic chemotherapy
in patients with metastatic MTC, only 29 % of patients
remained free of progression at 5 months after initiation of
treatment with a median overall survival of about 2 years
[14].
Recently, it has been revealed the importance of the
tyrosine kinase receptor RET (Rearranged During Trans-
fection) presented in the pathogenesis of MTC. RET
oncogene mutations occur in approximately 30–50 % of
sporadic MTC and in virtually all hereditary MTC. In
addition to these mutations, MTCs are associated with
other conditions of the tumor microenvironment, such as
high vascularization, as well as high levels of vascular
endothelial growth factor (VEGF), fibroblast growth factor
(FGF), and the platelet-derived growth factor (PDGF). This
fact shows that these tumors show a high capillary mi-
crodensity allowing neoplastic cells to enter the blood
vessels and spread to distant metastases [15].
While hereditary MTCs are traditionally diagnosed by
bilateral and multicentric tumors, sporadic MTCs usually
appear as a single nodule or as a unilateral palpable cer-
vical lymph node. In addition, a small group of patients
may present with systemic manifestations due to the
secretion of various peptides and vasoactive substances
that might produce similar symptoms to those of a carci-
noid syndrome with diarrhea, palpitations, facial flushing,
etc. Peptides that these tumors can produce and release into
the bloodstream comprise calcitonin, chromogranin A,
neurotensin, bombesin, somatostatin, vasoactive intestinal
peptide, carcinoembryonic antigen, calcitonin gene-related
peptide, and adrenocorticotropic hormone [16]. About
50 % of patients with MTC have tumors that extend
beyond the thyroid, mostly across the regional nodal level,
and 13 % have metastases at diagnosis. About 90 % of
patients with metastatic disease will die due to disease
progression.
Most new treatments against advanced MTC target the
cell membrane tyrosine kinase receptors. These receptors
are responsible for controlling the tumoral cell vital func-
tions such as cell differentiation, cell survival, prolifera-
tion, and motility. The main tyrosine kinase receptor
involved in MTC is the one derived from RET gene. Sev-
eral multitargeted kinase inhibitors are able to inhibit not
only RET but also other receptors involved in tumor pro-
liferation and angiogenesis [11]. Some of these multitar-
geted agents have shown activity in the MTC field [17, 18].
The paradigm for treating patients with advanced MTC
has changed in recent years. Thus, recently vandetanib has
been commercialized for the treatment of aggressive and
symptomatic patients with MTC in patients with locally
advanced or metastatic unresectable disease based on data
from the ZETA study [17]. Vandetanib treatment was able
to significantly increase progression-free survival com-
pared to the placebo in the first-line systemic treatment of
patients with locally advanced or metastatic MTC
(30.5 months vs. 19.3 months, HR, 0.46, 95 % CI,
0.31–0.69, P \ 0.001).
The phase III clinical trial called EXAM (Efficacy of
XL184 in Advanced Medullary Thyroid Cancer) has shown
that cabozantinib increases progression-free survival com-
pared with placebo in patients with progressing advanced
or metastatic MTC (11.2 months vs. 4 months, HR 0.28,
95 % CI 0.19–0.40, P \ 0.001) [18]. The increase in PFS
was observed consistently in all subgroups of patients
analyzed including age, treatment with a prior tyrosine
kinase inhibitor, presence or absence of RET mutation and
in sporadic and hereditary tumors.
Clin Transl Oncol (2014) 16:1035–1042 1039
123
Direct comparison of the pivotal clinical trials of cab-
ozantinib and vandetanib is not methodologically correct,
being impossible to extrapolate definitive conclusions
about which drug is more active and better tolerated. The
profile of patients treated in these studies is not
superimposable.
Based on the different safety profile and baseline char-
acteristics of the patients recruited in both EXAM and
ZETA trial and based on the clinical experience, the SEOM
proposes the following algorithm of treatment for non-
resectable and advanced MTC patients. (Figs. 1, 2) Both,
vandetanib and cabozantinib exert a IB level of evidence
for the indication and there is a need to find molecular
biomarkers that might help us to select the best options for
each patients and also the best sequencing treatment
strategy for them.
Multidisciplinary approach, experience in dealing with
advanced MTC and skills in the management of multitar-
geted agents emerge as crucial factors for the correct
management of advanced MTC patients in the daily clin-
ical practice.
Recommendations: Vandetanib and cabozantinib exert
a IB level of evidence for the indication of locally
advanced or metastatic unresectable MTC treatment.
Undifferentiated/Anaplastic thyroid carcinoma (ATC)
The undifferentiated/anaplastic thyroid carcinoma repre-
sents 1–2 % of malignant epithelial thyroid tumors. So far,
it is one of the most lethal malignancies in adults, with a
mortality approaching 100 % and a median survival of
3–5 months after diagnosis [19].
The ATC has a different genetic profile to differentiated
thyroid tumors. Some of these mutations, such as RAS and
BRAF, are common in differentiated and undifferentiated
thyroid tumors, suggesting that might occur in early stages
of carcinogenesis. About 90 % of the mutations of BRAF
are detected in the V600E variant. Other mutations such as
PI3K and PTEN can also be observed, although to a lesser
extent. Other genes such as TP53 and b-catenin (CTNNB1)
often have somatic mutations in the ATC.
Histological and immunohistochemical study of samples
during the diagnosis is required to exclude other forms of
differentiated thyroid cancer and potentially curable, as
well as other tumor types that may result in a differential
diagnosis.
All patients with ATC are designated as stage IV [20],
being able to distinguish between stage IVA (intrathyroidal
tumors), IVB, (extrathyroidal extension) and IVC (exis-
tence of distant metastases).
We always have to keep in mind that patients with ATC
may develop a quick symptomatic deterioration of their
general conditions and performance status. For that reason,
best supportive care may be the only therapeutic option in
most patients. There is no randomized clinical trial on
treatment of ATC alone because of their low prevalence.
As a consequence, the low grade of evidence is in general
the rule. Multiple descriptive studies with small sample
Fig. 2 Algorithm of treatment
for the management of
advanced MTC
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size have had conflicting results. They were performed
mostly in differentiated thyroid carcinoma but including
some cases of ATC.
Recommendation: Histological and immunohisto-
chemical study of samples is required to exclude other
forms of differentiated thyroid cancer and potentially cur-
able in the ATC diagnosis. Preoperative radiological
studies have to be performed in ATC including ultrasound,
CT scan or MRI (for neck and chest), and PET/CT scan.
Treatment of resectable localized or locally advanced
ATC (IVA and resectable IVB)
In patients with resectable disease at diagnosis, surgical
resection (total thyroidectomy together with central and
lateral cervical lymphadenectomy) should be performed
followed by adjuvant treatment with radiotherapy or con-
current chemoradiotherapy. In the case of incidental ATC
diagnosis, is not proven that performing total thyroidec-
tomy after partial thyroidectomy improves the prognosis of
the disease.
Adjuvant radiation therapy after surgical resection of
ATC has shown significant increase in survival [21].
Multiple studies suggest a possible benefit of combined
chemoradiotherapy after additional surgery, although any
randomized controlled study has succeeded in demon-
strating significant benefit compared to radiotherapy alone,
so there is no established standard treatment. Schemes
commonly used in combination chemotherapy in the
adjuvant setting include taxanes, platinum-based regimens,
and anthracyclines.
Therefore, adjuvant treatment should be used in all
patients with adequate performance status after complete
surgical resection (excluding incidental ATC). In those
patients with incomplete gross resection (R2), subsequent
salvage surgery can be considered.
Recommendation: Lobectomy or near-total thyroidec-
tomy with lateral and central node dissection should be
performed in ATC. Definitive radiation therapy with or
without concomitant chemotherapy should be offered to
ATC patients with adequate performance status.
Treatment of locally advanced ATC (unresectable IVB)
and advanced ATC (IVC)
Patients with unresectable ATC diagnosis without distant
metastases may benefit from neoadjuvant or adjuvant
radiotherapy or chemoradiotherapy. If complete or partial
response is observed it might consider a subsequent sur-
gery, provided a complete gross resection (R0/R1) possible
[22].
The priority in ATC patients with distant metastases
should be proper control of symptoms, as no randomized
study to demonstrate benefit in survival or quality of life.
Cytotoxic agents that have shown increased activity in
ATC are the taxanes with the highest response rate (50 %)
[23] and anthracyclines.
Several agents have been shown to have potential ben-
efit in preclinical studies, but many of them have failed to
demonstrate efficacy in clinical trials. Nevertheless, there
are recent positive results suggesting an improved outcome
of these patients in the near future. Imatinib has shown
variable activity in different cell lines of ATC. In a phase II
clinical trial with 11 patients, disease control was observed
in 6 of 8 patients evaluated, with a survival rate of 46 %
and a progression-free survival of 27 % at 6 months [24].
The combretastatin A4 has achieved satisfactory results in
phase II trial in combination with carboplatin and paclit-
axel, showing 35 % reduction in mortality risk and one-
year progression-free survival in 26 % of the patients [25].
In a phase II clinical trial, Sorafenib has shown 10 %
partial response rate and clinical benefit in 7 of 10 patients,
with a progression-free survival of 1.9 months and a
median survival of 3.9 months [26].
Recommendation: Neoadjuvant radiotherapy with or
without chemotherapy should be offered in unresectable
IVB patients. If response is observed, salvage surgery has
to be performed. Systemic chemotherapy based on taxanes
and/or anthracyclines should be offered in patients with
good performance status. New clinical trials may offer an
opportunity to improve the outcome in advanced ATC
patients. Other options are systemic chemotherapy, che-
moradiotherapy, radiotherapy alone or best supportive
care.
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